(Q38034908)

27 August 2017

title

The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient (English)

1 reference

27 August 2017

1 reference

1 reference

2

Daniel C Cattran

1 reference

27 August 2017

Jai Radhakrishnan

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

15 August 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

82

1 reference

27 August 2017

issue

8

1 reference

27 August 2017

page(s)

840-856

1 reference

Clinical guidelines: potential benefits, limitations, and harms of clinical guidelines

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Achieving health gain through clinical guidelines II: Ensuring guidelines change medical practice

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Podocyte foot process effacement as a diagnostic tool in focal segmental glomerulosclerosis.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Nephrotic Proteinuria Without Hypoalbuminemia: Clinical Characteristics and Response to Angiotensin-Converting Enzyme Inhibition

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Partial remission with cyclosporine A in a patient with nephrotic syndrome due to NPHS2 mutation.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Long-term effects of cyclosporine A in Alport's syndrome

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Necrotizing and crescentic lupus nephritis with antineutrophil cytoplasmic antibody seropositivity

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Predicting outcomes of lupus nephritis with tubulointerstitial inflammation and scarring

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

The effects of cyclophosphamide and mycophenolate on end-stage renal disease and death of lupus nephritis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Long-term outcomes--mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Rituximab in systemic lupus erythematosus: A systematic review of off-label use in 188 cases

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Management of membranous nephropathy: when and what for treatment

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Validation of a predictive model of idiopathic membranous nephropathy: its clinical and research implications.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

The natural history of the non-nephrotic membranous nephropathy patient

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Venous thromboembolism in patients with membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Early versus late start of immunosuppressive therapy in idiopathic membranous nephropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

A randomized trial of methylprednisolone and chlorambucil in idiopathic membranous nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Cyclosporine in patients with steroid-resistant membranous nephropathy: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Proteinuria patterns and their association with subsequent end-stage renal disease in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Remission of proteinuria improves prognosis in IgA nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Treatment of IgA nephropathy with ACE inhibitors: a randomized and controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Combination therapy of prednisone and ACE inhibitor versus ACE-inhibitor therapy alone in patients with IgA nephropathy: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Rituximab versus cyclophosphamide for ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Microscopic polyangiitis with alveolar hemorrhage. A study of 29 cases and review of the literature. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Prognostic factors for hospital mortality and ICU admission in patients with ANCA-related pulmonary vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2012.280

7 January 2021

Identifiers

DOI

10.1038/KI.2012.280

1 reference

Dimensions Publication ID

27 August 2017

1040336547

0 references

1 reference